icon-folder.gif   Conference Reports for NaTaP  
 
  EASL - The International Liver Congress 2015
50th annual Meeting of the European
association for the Study of the Liver
Vienna, austria  april 22-26
Back grey_arrow_rt.gif
 
 
 
Malachite-I Phase 3b Trial of Ombitasvir/Paritaprevir/r and Dasabuvir ± Ribavirin or Telaprevir + Peginterferon/Ribavirin in Treatment-Naďve Adults With Hcv Genotype 1
 
 
  Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
 
Brian Conway1, Ewa Janczewska2, Yan Luo3, Manuela Curescu4, Susan Greenbloom5, Adrian Streinu-Cercel6, Florin Alexandru Caruntu7, Wayne Ghesquiere8, Brygida Knysz9, Wodzimierz Mazur10, Adriana Motoc11, Alejandro Soza12, Victoria Arama6, Olav Dalgard13, Danielle Sullivan3, Xuan Liu3, Mudra Kapoor3, Yan Liu3, Andrew Campbell3, Thomas Podsadecki3
1Vancouver Infectious Diseases Centre, Vancouver, British Colombia, Canada; 2ID Clinic, Mysowice, Poland; 3AbbVie Inc., North Chicago, Illinois, United States; 4Clinic of Infectious Diseases, University of Medicine and Pharmacy Timisoara, Timisoara, Romania; 5Toronto Digestive Disease Associates, Toronto, Ontario, Canada; 6Carol Davila University of Medicine and Pharmacy, National Institute for Infectious Diseases, Bucharest, Romania; 7National Institute for Infectious Diseases "Prof. Dr. Matei Bals", Bucharest, Romania; 8Island Health Authority, Section of Infectious Diseases, Victoria, British Colombia, Canada; 9Wroclaw Medical University, Wroclaw, Poland; 10Clinical Department of Infectious Disease, Medical University of Silesia, Katowice, Poland; 11Hospital of Infectious Diseases Dr. Victor Babes, Bucharest, Romania; 12Department of Gastroenterology, Pontificia Universidad Católica de Chile, Santiago, Chile; 13Akershus University Hospital, Lorenskog, Norway

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif

EASL10.gif

EASL11.gif

EASL12.gif

EASL13.gif

EASL14.gif

EASL15.gif

EASL16.gif

EASL17.gif

EASL18.gif